CN103687964A - 用于预测患有癌症之对象对化疗之临床响应的方法 - Google Patents

用于预测患有癌症之对象对化疗之临床响应的方法 Download PDF

Info

Publication number
CN103687964A
CN103687964A CN201280035399.6A CN201280035399A CN103687964A CN 103687964 A CN103687964 A CN 103687964A CN 201280035399 A CN201280035399 A CN 201280035399A CN 103687964 A CN103687964 A CN 103687964A
Authority
CN
China
Prior art keywords
chokα
cancer
expression level
subject
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280035399.6A
Other languages
English (en)
Chinese (zh)
Inventor
胡安·卡洛斯·拉卡尔圣胡安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRANSLATIONAL CANCER DRUGS PHARMA SL
Original Assignee
TRANSLATIONAL CANCER DRUGS PHARMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSLATIONAL CANCER DRUGS PHARMA SL filed Critical TRANSLATIONAL CANCER DRUGS PHARMA SL
Publication of CN103687964A publication Critical patent/CN103687964A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280035399.6A 2011-06-20 2012-06-20 用于预测患有癌症之对象对化疗之临床响应的方法 Pending CN103687964A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11382211 2011-06-20
EP11382211.8 2011-06-20
US201161507833P 2011-07-14 2011-07-14
US61/507,833 2011-07-14
EP11382294.4 2011-09-16
EP11382294 2011-09-16
PCT/EP2012/061790 WO2012175537A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Publications (1)

Publication Number Publication Date
CN103687964A true CN103687964A (zh) 2014-03-26

Family

ID=47422050

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280035399.6A Pending CN103687964A (zh) 2011-06-20 2012-06-20 用于预测患有癌症之对象对化疗之临床响应的方法

Country Status (11)

Country Link
US (1) US20150004252A1 (enExample)
EP (1) EP2721174A1 (enExample)
JP (1) JP2014527397A (enExample)
KR (1) KR20140047664A (enExample)
CN (1) CN103687964A (enExample)
AU (1) AU2012274156A1 (enExample)
BR (1) BR112013032857A2 (enExample)
CA (1) CA2840129A1 (enExample)
MX (1) MX2013015286A (enExample)
RU (1) RU2014101492A (enExample)
WO (1) WO2012175537A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050668A (zh) * 2017-06-09 2017-08-18 南京医科大学第附属医院 基于云处理的放疗效果预测方法
CN109790164A (zh) * 2016-07-25 2019-05-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
CN111886499A (zh) * 2017-12-21 2020-11-03 瓦尔希伯伦私人肿瘤研究基金会 基于检测肿瘤细胞中rad51焦点的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
US20170305861A1 (en) * 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
CN110494570A (zh) 2017-03-29 2019-11-22 中美冠科生物技术（太仓）有限公司 确定癌症对卡仑尼替星敏感性的系统和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
CN102228689A (zh) * 2005-04-13 2011-11-02 科学研究高等机关 鉴定用于癌症治疗的化合物的体外方法
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
EP2316970A2 (en) * 2008-07-04 2011-05-04 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
EP2324123B1 (en) 2008-09-10 2016-07-20 Rutgers, The State University of New Jersey IMAGING INDIVIDUAL mRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE MOLINA ET AL.: "Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer:a retrospective study", 《LANCET ONCOLOGY》 *
RACHEL CAVILL ET AL.: "Consensus-phenotype intergration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumor cells", 《PLOS COMPUTATIONAL BIOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790164A (zh) * 2016-07-25 2019-05-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
CN109790164B (zh) * 2016-07-25 2022-01-25 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
CN107050668A (zh) * 2017-06-09 2017-08-18 南京医科大学第附属医院 基于云处理的放疗效果预测方法
CN107050668B (zh) * 2017-06-09 2020-03-31 南京医科大学第一附属医院 基于云处理的放疗效果预测方法
CN111886499A (zh) * 2017-12-21 2020-11-03 瓦尔希伯伦私人肿瘤研究基金会 基于检测肿瘤细胞中rad51焦点的方法

Also Published As

Publication number Publication date
BR112013032857A2 (pt) 2017-01-24
KR20140047664A (ko) 2014-04-22
MX2013015286A (es) 2014-09-25
US20150004252A1 (en) 2015-01-01
EP2721174A1 (en) 2014-04-23
WO2012175537A1 (en) 2012-12-27
AU2012274156A1 (en) 2014-01-23
JP2014527397A (ja) 2014-10-16
RU2014101492A (ru) 2015-07-27
CA2840129A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
EP2527460B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP5926487B2 (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
US20140302042A1 (en) Methods of predicting prognosis in cancer
CN103562406B (zh) 用于预测对艾日布林的反应的方法和组合物
HK1244847A1 (zh) 用於膀胱癌症的治疗，诊断和预後方法
HK1221422A1 (zh) 诊断方法和用於治疗成胶质细胞瘤的组合物
JP2006500946A (ja) 精巣精上皮腫の診断方法
CN103687964A (zh) 用于预测患有癌症之对象对化疗之临床响应的方法
EP4055194A1 (en) Iron-score and in vitro method for identifying mantle cell lymphoma (mcl) subjects and therapeutic uses and methods
TWI595879B (zh) Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
US20150017210A1 (en) Gene Signature Predicts Adenocarcinoma Prognosis and Therapeutic Response
US20220003770A1 (en) Classification and Treatment of Gastric Cancer
US20120316187A1 (en) Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP3794353B1 (en) Spag5 as a biomarker for breast cancer treatment
KR20100044851A (ko) Ｅｇｆｒ 억제제를 이용한 치료에 대한 예측 마커
JP2007522791A (ja) 結腸直腸癌を診断する方法
Babyshkina et al. Non-Smad TGF-β signaling components are possible biomarkers of tamoxifen resistance
WO2013151026A1 (ja) Ｐｉ３ｋ阻害剤耐性がん細胞用診断マーカー及び診断方法
AU2011265464A1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326